Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Dysthymia disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dysthymia, now known as persistent depressive disorder (PDD), is a mood disorder consisting of the same cognitive and physical problems as depression, with less severe but longer-lasting symptoms.
Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
InactiveUS20090088404A1Act quicklyReduce riskBiocideNervous disorderS-Adenosyl-l-methioninePharmaceutical formulation
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
InactiveUS20090197824A1Act quicklyReduce riskBiocideNervous disorderS-Adenosyl-l-methioninePharmaceutical formulation
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Extended release pharmaceutical formulations of s-adenosylmethionine
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. majorclinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Use of enantiomeric pure escitalopram
The present invention relates to the use of anatiomeric pure escitalopram and / or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.
Owner:H LUNDBECK AS
Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
InactiveUS20080206333A1Improved pharmacokinetic propertiesAct quicklyBiocideNervous disorderS-Adenosyl-l-methioninePharmaceutical formulation
Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.
Owner:METILEJSHN SAJENSIS INT SRL
Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
S-adenosylmethionine formulations with enhanced bioavailability
InactiveUS20130142847A1Reduce penetrationImprove bioavailabilityBiocideNervous disorderImmunologic disordersS-Adenosyl-l-methionine
Owner:MSI METHYLATION SCI
Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
Owner:WYETH LLC
Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan
Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH
Methods for diagnosing mood disorders
InactiveUS20120321644A1Lower Level RequirementsAvoid generatingNervous disorderMicrobiological testing/measurementDiseaseFibril
The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a mood disorder such as a major or minor depressive disorder or dysthymia attributed to reduced levels of Aβ protein, including Aβ1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders and methods of identifying subjects who may respond positively to such treatment by administering an agent that either prevents production of Aβ, prevents aggregation of Aβ fibrils, that increases the degradation or clearance of Aβ or that prevents or interferes with Abeta-induced neurotoxicity.
Owner:NEW YORK UNIV
Traditional Chinese medicine composition for treating dysthymia
InactiveCN102357169AImprove depressive behaviorNervous disorderPlant ingredientsExperimental methodsAdditive ingredient
The invention relates to a traditional Chinese medicine composition for treating dysthymia, belonging to traditional Chinese medicines. The traditional Chinese medicine composition for treating dysthymia is prepared from the following active pharmaceutical ingredients in parts by weight: 27-33 parts of rhizoma cyperi, 8-12 parts of hemlock parsley, 8-12 parts of gardenia, 8-12 parts of rhizoma atractylodis, 27-33 parts of poria with hostwood, 12-18 parts of angelica and 8-12 parts of radix bupleuri. According to the traditional Chinese medicine theoretical formula, the modern pharmacological experimental method sufficiently proves that the traditional Chinese medicine composition for treating dysthymia has the functions of soothing the liver, regulating the flow of qi and relieving the depressed liver, is used for treating dysthymia, and is suitable for patients with depression and stagnation of the liver-qi in traditional Chinese medicine.
Owner:王剑
A robot for music-assisted physiotherapy for mental depression
InactiveCN102274571AHelps relieve mental stressWide range of usesSleep/relaxation inducing devicesPatient needEngineering
A robot for music-assisted physiotherapy for mental depression, which is composed of a body and a power circuit, an inductive sensor, a transponder and a player. The upper part of the body is the robot head, and the lower part is the feet. Start switch and close switch, inductive sensor, system processor and pronunciation device are formed, and inductive sensor is arranged on the top of robot, and start and close switch and plug are arranged on body and biped. When the patient needs to relieve stress, turn on the power, turn on the switch, and play comforting sounds, soothing light music and happy songs through man-machine dialogue interaction induction to relieve the patient's mental stress.
Owner:龙梅
Treatment for depressive disorders
InactiveCN101448805AOrganic active ingredientsNervous disorderBULK ACTIVE INGREDIENTAntipsychotic Medications
The present invention provides a method for treating a depressive disorder which comprises a dministering a melatonin agonist alone, or in combination wit additional ant idepressant medication(s). The depressive disorder treated is one or more of major depression, dysthymia or bipolar disorder. A kit is also provided com prising one or more pharmaceutical dose units of a melatonin agonist and oneor more pharmaceutical dose units of an antidepressant. The individual dose .units may each further comprise an antidepressant or antipsychotic, and opt ionally one or more pharmaceutically active ingredients.
Owner:VANDA PHARMA INC
Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
InactiveUS7795385B2Lessen lung damageImprove survivalAntibacterial agentsNervous disorderModerate depressionGastrin-releasing peptide
The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.
Owner:CRISTALIA PROD QUI FARM LTDA
Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
Compounds of the formula useful for the treatment of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse, and dysthymia.
![Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine](https://images-eureka.patsnap.com/patent_img/1485c612-4153-4191-8c07-52bcfa72c6f0/US06987117-20060117-C00001.png "Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine")
![Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine](https://images-eureka.patsnap.com/patent_img/1485c612-4153-4191-8c07-52bcfa72c6f0/US06987117-20060117-C00002.png "Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine")
![Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine](https://images-eureka.patsnap.com/patent_img/1485c612-4153-4191-8c07-52bcfa72c6f0/US06987117-20060117-C00003.png "Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine")
Owner:WYETH
Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
InactiveUS20090042874A1Shorten the incubation periodIncreased serotonin levelBiocideNervous disorderDiseaseAttention deficits
The invention provides compounds of the Formula:that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
InactiveCN101090731AAntibacterial agentsNervous disorderModerate depressionGastrin-releasing peptide
Owner:CRISTALIA PROD QUI FARM LTDA
Methods for Diagnosing Mood Disorders
InactiveUS20150226751A1Lower Level RequirementsAvoid generatingNervous disorderMicrobiological testing/measurementFibrilBlood plasma
The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a mood disorder such as a major or minor depressive disorder or dysthymia attributed to reduced levels of Aβ protein, including Aβ1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders and methods of identifying subjects who may respond positively to such treatment by administering an agent that either prevents production of Aβ, prevents aggregation of Aβ fibrils, that increases the degradation or clearance of Aβ or that prevents or interferes with Abeta-induced neurotoxicity.
Owner:POMARA NUNZIO
Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Antidepressant piperidine derivatives of heterocyclefused benzodioxans
Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
The compound 4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine according to the structure (formula I), and pharmaceutically acceptable salts thereof are provided for the treatment of CNS related disorders, such as: depressive disorder, dysthymic disorder; mood disorder due to a general medical condition; atypical depression; seasonal affective disorder; melancholia; treatment resistant depression; partial responders; depression associated with bipolar disorder, pain, Alzheimer's disease, psychosis, Parkinson's disease, Lewy body disease, Huntington's disease, multiple sclerosis or anxiety; general anxiety disorder, social anxiety disorder, panic attacks; phobia; social phobia, obsessive compulsive disorder; post traumatic stress disorder, acute stress; ADHD; and pain.
![4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine](https://images-eureka.patsnap.com/patent_img/13264ff2-4046-40b5-8301-1bda1efbba26/US20110039890A1-20110217-C00001.png "4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine")
![4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine](https://images-eureka.patsnap.com/patent_img/13264ff2-4046-40b5-8301-1bda1efbba26/US20110039890A1-20110217-C00002.png "4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine")
![4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine](https://images-eureka.patsnap.com/patent_img/13264ff2-4046-40b5-8301-1bda1efbba26/US20110039890A1-20110217-C00003.png "4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine")
Owner:H LUNDBECK AS
Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
Compounds of the formula useful for the treatment of diseases such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Medicament for treating dysthymia
InactiveCN103142969AImprove securityClear curative effectNervous disorderPlant ingredientsRhizomeChrysomya
The invention relates to a medicament for treating dysthymia. The medicament is prepared from the following substances in parts by weight: 5-10 parts of radix scrophulariae, 10-20 parts of rhizoma zingiberis, 20-30 parts of dogwood, 10-20 parts of platycodon grandiflorum, 15-25 parts of goldthread, 5-15 parts of chrysanthemum, 10-30 parts of golden-rod, 1-15 parts of henbane, 10-20 parts of ephedra, 15-30 parts of pyrrosia lingua, 20-30 parts of tabasheer, 1-20 parts of morinda officinalis, 1-20 parts of rhizoma dioscoreae, 10-25 parts of lalang grass rhizome, 10-30 parts of cocklebur fruit, 1-20 parts of emblic leafflower fruit, 15-20 parts of kamuning, 10-20 parts of kaladana, 15-20 parts of herba inulae, 15-30 parts of herb of glabrous sarcandra, 10-20 parts of fructus aristolochiae, 10-25 parts of folium sennae, 5-15 parts of aleppo avens, 1-20 parts of uniflower swisscentaury root, 15-25 parts of rhododendron dauricum, 15-25 parts of potentilla discolor, 10-20 parts of chinese lantern-plant, 15-25 parts of root bark of white mulberry, 20-30 parts of common vladimiria root, 1-20 parts of gorgon fruit and 10-25 parts of chinese azalea flower. All components of the medicament for treating dysthymia disclosed by the invention are natural materials; and the medicament is good in security, definite in curative effect, and suitable for large-scale clinical popularization.
Owner:高新华
Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
Owner:WYETH LLC
Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
Compounds of the formula useful for the treatment of diseases such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan
Compounds of the Formula I: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Medicament for treating multiple diseases such as climacteric syndrome and osteoporosis of women
ActiveCN101172103BInhibit apoptosisIncrease contentNervous disorderSkeletal disorderDiseaseMale infertility
The invention relates to medicine for remedying women climacteric syndrome, osteoprosis, dysthymia, premature ovarian failure, premenstruum stress syndrome, hyperthyroidism, male and female Female / male infertility symptom, alopeia and leucotrichia and other diseases. The utility model is characterized in that the medicine comprises fatty acid within the scope of following weight parts: 8 to 32 percent of hexadecanoic acid, 11 to 35 percent of hexadecenoic acid, 13 to 33 percent of octadecenic acid, 0.3 to 2.5 percent of octadecanoic acid, 11 to 33 percent of octadecadienoic acid and 3 to 15 percent of calendic acid. Compared with other medicine, the medicine has simple component, belongs to target organ excitant, and has the function of self reversible adjustment to the second messenger substance of the organism. The invention belongs to medicine with high, safe and streamlined curative effect.
Owner:ZHEJIANG INNOVATION WISDOM VALLEY TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com